Free Trial
→ I’m sounding the alarm (From Porter & Company) (Ad)tc pixel Free NVCT Stock Alerts

Nuvectis Pharma (NVCT) Stock Forecast & Price Target

Nuvectis Pharma logo
$10.00 +0.29 (+2.99%)
Closing price 04:00 PM Eastern
Extended Trading
$9.82 -0.19 (-1.85%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

Nuvectis Pharma - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold
Based on 2 Analyst Ratings
Sell
1
Hold
0
Buy
1

Based on 2 Wall Street analysts who have issued ratings for Nuvectis Pharma in the last 12 months, the stock has a consensus rating of "Hold." Out of the 2 analysts, 1 has given a sell rating, and 1 has given a buy rating for NVCT.

Consensus Price Target

$10.00
N/A
According to the 2 analysts' twelve-month price targets for Nuvectis Pharma, the average price target is $10.00. The highest price target for NVCT is $10.00, while the lowest price target for NVCT is $10.00. .
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for NVCT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Nuvectis Pharma and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NVCT Analyst Ratings Over Time

TypeCurrent Forecast
5/6/25 to 5/6/26		1 Month Ago
4/6/25 to 4/6/26		3 Months Ago
2/5/25 to 2/5/26		1 Year Ago
5/6/24 to 5/6/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$10.00$10.00$15.33$17.00
Forecasted UpsideN/A30.72% Upside82.32% Upside89.73% Upside
Consensus RatingHoldHoldModerate BuyBuy

NVCT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NVCT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Nuvectis Pharma Stock vs. The Competition

TypeNuvectis PharmaMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.30
2.52
Consensus RatingHoldHoldModerate Buy
Predicted Upside1.21% Upside975.28% Upside14.01% Upside
News Sentiment Rating
Positive News

See Recent NVCT News
Positive News
Positive News
Export
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
1/22/2026
Weiss Ratings logo
Weiss Ratings
Not Rated
 Reiterated RatingSell (E+)
12/3/2025
HC Wainwright logo
HC Wainwright
3 of 5 stars
Joseph Pantginis
3 of 5 stars
Reiterated RatingBuy
4/2/2025
Maxim Group logo
Maxim Group
1 of 5 stars
Naz Rahman
Not Rated
Initiated CoverageBuy$17.00+81.82%
3/17/2025
Laidlaw logo
Laidlaw
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Yale Jen
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Initiated CoverageBuy$19.00+114.69%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 05:47 PM ET.


NVCT Forecast - Frequently Asked Questions

According to the research reports of 2 Wall Street equities research analysts, the average twelve-month stock price forecast for Nuvectis Pharma is $10.00, with a high forecast of $10.00 and a low forecast of $10.00.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nuvectis Pharma in the last year. There is currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" NVCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVCT, but not buy additional shares or sell existing shares.

Analysts like Nuvectis Pharma less than other "medical" companies. The consensus rating score for Nuvectis Pharma is 2.00 while the average consensus rating score for "medical" companies is 2.30. Learn more on how NVCT compares to other companies.

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Nuvectis Pharma Recommendations


This page (NASDAQ:NVCT) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
The Iran War Just Broke the Gold Market
The Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged...
Behind the Markets | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
BlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?
BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...
Awesomely, LLC | Sponsoredtc pixel
Military ‘Dark Energy’ to Power AI
When it was put inside U.S. tanks, they moved almost silently and produced no smoke. Now, Elon Musk is using t...
Altimetry | Sponsoredtc pixel
One executive order. The biggest wealth transfer of your lifetime.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Trump and Elon are BACK
15X Bigger Than SpaceX: Elon's New Launch While the rest of the market goes crazy for "the mother of all IP...
InvestorPlace | Sponsoredtc pixel